GSK3145095 is an investigational small molecule inhibitor targeting the enzyme arginase, which plays a role in modulating immune responses in the tumor microenvironment. By inhibiting arginase, this compound helps restore T-cell function, which can be suppressed in cancer settings due to arginine depletion. This mechanism supports enhanced anti-tumor immunity, making GSK3145095 a potential candidate for cancer immunotherapy. It has been evaluated in clinical trials, particularly for solid tumors, to assess its safety and efficacy either as a monotherapy or in combination with other immune checkpoint inhibitors like anti-PD-1 agents. The primary therapeutic focus is on leveraging the compound’s immunomodulatory effects to improve patient response to cancer treatment.